Methylation is one of the body’s most important and most common chemical processes. Methylation processes occur in hundreds of essential chemical reactions in our bodies and play an important role in many critical processes. In this podcast, Dr. Paul Anderson explores how the understanding of methylation status beyond MTHFR gene variations can help to guide therapy and improve health.
MTHFR is an enzyme that adds a methyl group to folic acid to make it usable by the body. The MTHFR gene produces this enzyme that is necessary for properly using vitamin B9 and is also important for converting homocysteine into methionine, which the body needs for proper metabolism and muscle growth and which is needed for glutathione creation . The process of methylation also involves the enzyme from the MTHFR gene, so those with a mutation may have trouble effectively eliminating toxins from the body. In this podcast, Dr. Paul Anderson answers the questions: What is methylation, how does it relate to the MTHFR defect and how does this affect our health?
Coming up with new drug delivery techniques that can precisely target cancer cells, while leaving healthy tissue unharmed, has been a major goal for cancer researchers in recent years. Scientists at the University of Manchester have been testing a new approach that relies on liposomes. The new studies demonstrate for the first time how they can be built to include a temperature control, which could be an effective way of targeting treatment towards cancer cells while leaving healthy cells unharmed.
Researchers are finding new evidence that suggests genetics play a role in immune response, affecting our ability to fight off disease. There are also recently discovered mechanisms that regulate the expression of our genes and are influenced by environmental factors. In this podcast, Dr. Paul Anderson answers the questions: How do genes work and what can affect them after we are born? How do they “code” for immune function and what can you do about your genes?
The virtual doctor visit has arrived. The consulting firm Deloitte has predicted that out of an average 600 million general practitioner appointments in the U.S. and Canada this year, up to 75 million could be e-visits. Even if only 30% to 40% of office visits are replaced by e-visits, that could make up a $50 to $60 billion market. Insurers, hospitals, and even drugstore giant Walgreens are embracing the technology as a way to control costs and deliver more care in the face of a growing doctor shortage.